BR112014025206A2 - filme oral contendo pérolas de liberação entérica de opiato - Google Patents

filme oral contendo pérolas de liberação entérica de opiato

Info

Publication number
BR112014025206A2
BR112014025206A2 BR112014025206A BR112014025206A BR112014025206A2 BR 112014025206 A2 BR112014025206 A2 BR 112014025206A2 BR 112014025206 A BR112014025206 A BR 112014025206A BR 112014025206 A BR112014025206 A BR 112014025206A BR 112014025206 A2 BR112014025206 A2 BR 112014025206A2
Authority
BR
Brazil
Prior art keywords
oral
release
oral film
enteric
release beads
Prior art date
Application number
BR112014025206A
Other languages
English (en)
Other versions
BR112014025206B1 (pt
Inventor
Hsin Chwen Li Michael
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of BR112014025206A2 publication Critical patent/BR112014025206A2/pt
Publication of BR112014025206B1 publication Critical patent/BR112014025206B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Abstract

resumo patente de invenção: "filme oral contendo pérolas de liberação entérica de opiato". a presente invenção refere-se a uma dosagem de filme oral comestível ou wafer oral de liberação de droga opiato resistente a abuso e de liberação controlada para tratar dor e abuso de substância é provida. a dosagem de filme oral comestível ou wafer oral de liberação de droga inclui uma camada de liberação controlada contendo perolas de liberação entérica dispersas em uma matriz polímero. as pérolas de liberação entérica são formadas de uma quantidade terapêutica de um agonista de opióide e/ou seu sal farmaceuticamente aceitável e uma quantidade sub-terapêutica de antagonista de opióide e/ou seu sal farmaceuticamente aceitável revestida ou encapsulada em um polímero de liberação entérica. a matriz polímero de liberação controlada dissolve ou desintegra seguindo administração ou consumo do wafer oral ou filme oral comestível, liberando as pérolas de liberação entérica para serem engolidas, com subseqüente absorção dos ingredientes ativos dentro dos intestinos do paciente.
BR112014025206-8A 2012-04-12 2013-04-11 Método de fabricação de uma dosagem de filme oral compreendendo pérolas de liberação entérica BR112014025206B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/445,716 US9687445B2 (en) 2012-04-12 2012-04-12 Oral film containing opiate enteric-release beads
US13/445,716 2012-04-12
PCT/EP2013/057552 WO2013153145A1 (en) 2012-04-12 2013-04-11 Oral film containing opiate enteric-release beads

Publications (2)

Publication Number Publication Date
BR112014025206A2 true BR112014025206A2 (pt) 2017-07-11
BR112014025206B1 BR112014025206B1 (pt) 2022-04-19

Family

ID=48050757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025206-8A BR112014025206B1 (pt) 2012-04-12 2013-04-11 Método de fabricação de uma dosagem de filme oral compreendendo pérolas de liberação entérica

Country Status (9)

Country Link
US (2) US9687445B2 (pt)
EP (1) EP2836197B1 (pt)
JP (1) JP6254148B2 (pt)
CN (1) CN104271114B (pt)
BR (1) BR112014025206B1 (pt)
CA (1) CA2869450C (pt)
ES (1) ES2745210T3 (pt)
HK (1) HK1201718A1 (pt)
WO (1) WO2013153145A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927626B2 (en) 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20160175296A1 (en) * 2014-12-23 2016-06-23 Arx, Llc Method of producing uniform buprenorphine-containing formulations
EP3248595A4 (en) * 2015-01-22 2018-07-11 Nipro Corporation Film preparation
US10183018B2 (en) 2015-05-28 2019-01-22 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US11234974B2 (en) 2015-05-28 2022-02-01 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
GB201511284D0 (en) * 2015-06-26 2015-08-12 Univ Witwatersrand Jhb An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
US10662146B2 (en) 2015-09-15 2020-05-26 Praxis Bioresearch, LLC Prodrugs of fencamfamine
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
WO2019058172A1 (en) * 2017-09-07 2019-03-28 Nls-1 Pharma Ag MAZINDOLE TREATMENT FOR HEROID DEPENDENCE AND DISORDER RELATED TO THE USE OF PSYCHOACTIVE SUBSTANCES
FR3084837B1 (fr) * 2018-08-10 2021-10-29 Urgo Rech Innovation Et Developpement Composition filmogene mucoadhesive et son utilisation pour le traitement des douleurs liees aux poussees dentaires
DE102020112422A1 (de) 2020-05-07 2021-11-11 Lts Lohmann Therapie-Systeme Ag Verfahren zur Herstellung eines oralen Dünnfilms umfassend Mikropartikel
DE102021105268A1 (de) 2021-03-04 2022-09-08 Lts Lohmann Therapie-Systeme Ag. Oraler Dünnfilm
GB202214721D0 (en) 2022-10-06 2022-11-23 Rewire Therapeutics Ltd A treatment for mental disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335029B1 (en) 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7029700B2 (en) * 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
OA12215A (en) * 2000-02-08 2006-05-09 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
IL160222A0 (en) * 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
US8343546B2 (en) 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
DE102006027793A1 (de) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Opioid-Kombinations-Wafer
DE102006027795A1 (de) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Raucherentwöhnungs-Kombinationswafer
DE102006027792A1 (de) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
DE102006027791A1 (de) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag AchE-NMDA-Kombinationswafer
DE102006027796A1 (de) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
DE102006027794A1 (de) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antihypertonie-Kombinationswafer
DE102006027790A1 (de) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Typ-2-Diabetes Kombinations-Wafer
US20100285130A1 (en) * 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
EP2467126A1 (en) * 2009-08-19 2012-06-27 Bayer Pharma Aktiengesellschaft Drug delivery systems (wafer) for pediatric use
US20110195989A1 (en) * 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids

Also Published As

Publication number Publication date
US9687445B2 (en) 2017-06-27
ES2745210T3 (es) 2020-02-28
CA2869450A1 (en) 2013-10-17
CA2869450C (en) 2020-06-02
BR112014025206B1 (pt) 2022-04-19
JP2015512924A (ja) 2015-04-30
EP2836197A1 (en) 2015-02-18
US20130273162A1 (en) 2013-10-17
US20150064231A1 (en) 2015-03-05
HK1201718A1 (en) 2015-09-11
JP6254148B2 (ja) 2017-12-27
CN104271114A (zh) 2015-01-07
EP2836197B1 (en) 2019-06-19
US9763879B2 (en) 2017-09-19
CN104271114B (zh) 2019-12-03
WO2013153145A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
BR112014025206A2 (pt) filme oral contendo pérolas de liberação entérica de opiato
ES2925951T3 (es) Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
HRP20200600T1 (hr) Tapentadol za sprječavanje i liječenje depresije i tjeskobe
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
BRPI0708640A8 (pt) composição farmacêutica, e, métodos para tratar um paciente com dor de cabeça de enxaqueca, para tratar um paciente com dor e para tratar um paciente com enxaqueca
BR112014016085A8 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
JP2008044951A5 (pt)
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
JP2009525343A5 (pt)
Raffa et al. Oxycodone combinations for pain relief
EA201400972A1 (ru) Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
JP2013541583A5 (pt)
WO2008073344A1 (en) Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
Chen et al. Transdermal rotigotine: A clinically innovative dopamine‐receptor agonist for the management of Parkinson's disease
WO2007120485A2 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
AR084093A1 (es) Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
JP2019530706A5 (pt)
JP2012505830A5 (pt)
Elbaridi et al. Current concepts of phenylpiperidine derivatives use in the treatment of acute and chronic pain
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
ES2950507T3 (es) Tratamiento y gestión del aumento del síndrome de piernas inquietas
WO2008120966A1 (es) Composición farmacéutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgésico opiáceo para el manejo del dolor.
BR112020003025A2 (pt) métodos de tratamento de osteoartrite com gel transdérmico de canabidiol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/04/2013, OBSERVADAS AS CONDICOES LEGAIS.